<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473809</url>
  </required_header>
  <id_info>
    <org_study_id>07052015</org_study_id>
    <nct_id>NCT02473809</nct_id>
  </id_info>
  <brief_title>The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function</brief_title>
  <acronym>LIRABONE</acronym>
  <official_title>The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether liraglutide, a drug approved and widely used in
      the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2
      diabetes may cause multiple complications, and it is well known that patients with type 2
      diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a
      positive effect on bone, this may be one among other factors to consider before the decision
      about specific treatment of type 2 diabetes is made for the individual patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Type 2 diabetes may cause complications such as ischemic heart disease,
      nephropathy, neuropathy, and retinopathy. Several epidemiologic and animal studies also
      suggest that fracture risk is increased in diabetes.

      Bone is remodelled throughout life through bone resorption by the bone resorbing cells, the
      osteoclasts, and by bone formation by the bone forming cells, the osteoblasts. Bone
      remodelling can be monitored by biochemical markers of bone turnover and the effect of bone
      remodelling can be measured by changes in bone mineral density (BMD) by Dual X-ray
      absorptiometry (DXA) or bone structure by quantitative CT (QCT) or high resolution peripheral
      QCT (HRpQCT). The remodelling activity and the balance between resorption and formation are
      influenced by many factors including food consumption. The gut hormone glucagon-like
      polypeptide 1 (GLP-1) is released in relation to food intake and reduces serum levels of
      glucagon, increases serum levels of insulin, and reduces blood glucose in diabetes.
      Liraglutide is a GLP-1 analogue and has been approved for the treatment of type 2 diabetes.

      Aim: To investigate the effect of the GLP-1 analogue Liraglutide on bone turnover, bone mass,
      and bone structure in patients with type 2 diabetes.

      Methods: The clinical study will be conducted as a randomised, double-blinded,
      placebo-controlled, prospective, clinical trial with comparative treatment regimes with
      either subcutaneous Liraglutide or subcutaneous placebo injections.

      Perspectives: The project will bring new knowledge about the possible effects of GLP-1
      analogues on bone turnover and structure. This is important given that type 2 diabetes
      deteriorates bone health and increases risk of fractures. If Liraglutide can be demonstrated
      to have a positive effect on bone, this may be one among other factors to consider before the
      decision about specific treatment of type 2 diabetes is made for the individual patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in collagen I cross-linked C-terminal telopeptide measured in serum</measure>
    <time_frame>Days 0, 7, 28, 90, 180</time_frame>
    <description>Collagen I cross-linked C-terminal telopeptide has been chosen as primary endpoint as the expected mechanism of action is reduction in bone resorption, and as it is the most responsive bone resorption marker.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone alkaline phosphatase measured in serum</measure>
    <time_frame>Days 0, 7, 28, 90, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMD evaluated by DXA</measure>
    <time_frame>Days 0, 90, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone structure evaluated by QCT and HRpQCT</measure>
    <time_frame>Days 0, 90, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Days 0, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in osteocalcin measured in serum</measure>
    <time_frame>Days 0, 7, 28, 90, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in procollagen type I N-terminal propeptide measured in serum</measure>
    <time_frame>Days 0, 7, 28, 90, 180</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Complications</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide (&quot;Victoza&quot;), subcutaneous 1,8 mg once daily for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline, subcutaneous once daily for 180 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Diagnosis of type 2 diabetes (HbA1c &gt; 48 mmol/mol)

          -  Age older than 30 years

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Treatment with insulin

          -  Body weight &gt; 140 kg

          -  HbA1c &gt; 75 mmol/mol

          -  Treatment with GLP-1 analogues, Dipeptidyl peptidase-4 inhibitors, or glitazones

          -  Chronic kidney disease

          -  Hepatic disease

          -  Pancreatitis

          -  Inflammatory bowel disease

          -  Osteoporosis

          -  Family or personal history of medullary thyroid carcinoma

          -  Treatment with glucocorticoids

          -  Hormone replacement therapy

          -  Diabetic gastroparesis

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente L Langdahl, MD PhD DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrine Hygum, MD</last_name>
    <phone>+45 22154218</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus C</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrine Hygum, MD</last_name>
      <phone>+45 22154218</phone>
      <email>katrhygu@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Fehmann HC, Hering BJ, Wolf MJ, Brandhorst H, Brandhorst D, Bretzel RG, Federlin K, Göke B. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas. 1995 Aug;11(2):196-200.</citation>
    <PMID>7479679</PMID>
  </reference>
  <reference>
    <citation>Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012 Nov;27(11):2231-7. doi: 10.1002/jbmr.1759. Epub 2012 Sep 28. Review.</citation>
    <PMID>23023946</PMID>
  </reference>
  <reference>
    <citation>Schwartz AV, Sellmeyer DE. Diabetes, fracture, and bone fragility. Curr Osteoporos Rep. 2007 Sep;5(3):105-11. Review.</citation>
    <PMID>17925191</PMID>
  </reference>
  <reference>
    <citation>Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007 Apr;18(4):427-44. Epub 2006 Oct 27. Review.</citation>
    <PMID>17068657</PMID>
  </reference>
  <reference>
    <citation>Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008 Feb;149(2):574-9. Epub 2007 Nov 26.</citation>
    <PMID>18039776</PMID>
  </reference>
  <reference>
    <citation>Nuche-Berenguer B, Lozano D, Gutiérrez-Rojas I, Moreno P, Mariñoso ML, Esbrit P, Villanueva-Peñacarrillo ML. GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol. 2011 May;209(2):203-10. doi: 10.1530/JOE-11-0015. Epub 2011 Mar 3.</citation>
    <PMID>21372151</PMID>
  </reference>
  <reference>
    <citation>Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015 Feb;48(1):107-15. doi: 10.1007/s12020-014-0361-4. Epub 2014 Jul 30. Review.</citation>
    <PMID>25074632</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

